A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

NCT02053636 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
76
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institut de Recherches Internationales Servier

Collaborators